Vascular remodeling therapies for PAH behind Merck’s sotatercept

Phase III data from Merck’s sotatercept in pulmonary arterial hypertension bring the first therapy designed to counteract the excessive cell proliferation underlying the disease pathology closer to market, but the late-stage pipeline holds several other agents also aimed vascular remodeling.

Approved therapies for pulmonary arterial hypertension hit several different pathways, but all converge on the same therapeutic goal: vasodilation. ...